Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 10 Jun 2015
Revised: 07 May 2016
Accepted: 08 May 2016
First published online: 29 Jun 2016

Article Access Statistics
Abstract Page Views: 314
PDF Downloads: 221
Full Text Views: 0

Adv Pharm Bull. 2016;6(2):211-218 doi: 10.15171/apb.2016.029

D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension

Research Article

Elham Ghasemian 1, Parisa Motaghian 1, Alireza Vatanara 1 *

1 Pharmaceutics Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.



Abstract
Purpose: Bosentan is a drug currently taken orally for the treatment of pulmonary arterialhypertension. However, the water solubility of bosentan is very low, resulting in lowbioavailability. The aim of this study was preparation and optimization of bosentannanosuspension to improve solubility and dissolution rate.Methods: The different formulations designed by Design Expert® software.Nanosuspensions were prepared using precipitation method and the effects of stabilizer typeand content and drug content on the particle size, polydispersity (PDI) and yield ofnanosuspensions were investigated.Results: Particle size, PDI and yield of the optimal nanosuspension formulation were 200.9nm, 0.24 and 99.6%, respectively. Scanning electron microscopy (SEM) results showedspherical morphology for bosentan nanoparticles. Thermal analysis indicated that there wasa partial crystalline structure and change in the pholymorphism of bosentan in thenanoparticles. In addition, reduction of particle size, significantly increased in vitrodissolution rate of the drug.Conclusion: Optimization by design expert software was shown to be a successful methodfor optimization and prediction of responses by less than 10% error and formulation with15.8 mg span 85 as an internal stabilizer and 45 mg drug content were introduced as theoptimum formulation. The solubility of bosentan in the optimal formulation was 6.9 timeshigher than coarse bosentan and could be suggested as promising drug delivery systems forimproving the dissolution rate and possibly the pharmacokinetic of bosentan.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Ghasemian E
Articles by Motaghian P
Articles by Vatanara A

PubMed
Articles by Ghasemian E
Articles by Motaghian P
Articles by Vatanara A



Share this article!

Press Manuscript Online. Powered by MAADRAYAN